A5060685851- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- DNA Repair Mechanisms
- RNA modifications and cancer
- Salivary Gland Tumors Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Neuroendocrine Tumor Research Advances
- Ear and Head Tumors
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Gastric Cancer Management and Outcomes
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Tumors and Oncological Cases
- Head and Neck Surgical Oncology
- HIV Research and Treatment
- Esophageal Cancer Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Brain Metastases and Treatment
- Head and Neck Cancer Studies
- HER2/EGFR in Cancer Research
- Immune Cell Function and Interaction
The University of Texas MD Anderson Cancer Center
2019-2025
The University of Texas Health Science Center at Houston
2024
Argos Therapeutics (United States)
2016-2017
Durham University
2013
University Hospital of Wales
2012
Small cell lung cancer (SCLC) is an aggressive malignancy composed of distinct transcriptional subtypes, but implementing subtyping in the clinic has remained challenging, particularly due to limited tissue availability. Given known epigenetic regulation critical SCLC programs, we hypothesized that subtype-specific patterns DNA methylation could be detected tumor or blood from patients. Using genomic-wide reduced-representation bisulfite sequencing (RRBS) two cohorts totaling 179 patients...
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) CTLA4 inhibitors and PD-1 or PD-L1 (hereafter, PD-(L)1 inhibitors) is associated higher rates of anti-tumour activity immune-related toxicities, when compared treatment alone. However, there are currently no validated biomarkers to identify which will benefit from ICB1,2. Here we show that NSCLC who have mutations in the STK11 and/or KEAP1 tumour suppressor genes derived clinical ICB...
Abstract Purpose: Radiotherapy with or without chemotherapy is a mainstay of treatment for locally advanced non–small cell lung cancer (NSCLC), but no predictive markers are currently available to select patients who will benefit from these therapies. In this study, we investigated the association between alterations in STK11/LKB1, second most common tumor suppressor NSCLC, and response radiotherapy as well potential therapeutic approaches improve outcomes. Experimental Design: We conducted...
AGS-004 consists of matured autologous dendritic cells co-electroporated with in vitro transcribed RNA encoding HIV antigens. In an open-label, single arm sub-study AGS-004-003, was administered monthly to suppressed participants who started antiretroviral therapy (ART) during acute infection. HIV-1 specific T cell responses were measured by multicolor flow cytometry after 3-4 doses. The frequency resting CD4+ T-cell infection (RCI) quantitative viral outgrowth assay. Participants...
Abstract Small cell lung cancer (SCLC) remains the deadliest histologic subtype with a median survival of only ∼12 months among patients extensive stage (ES) disease. SCLC is strongly associated heavy tobacco use, yet effect use on therapeutic outcomes understudied. Recent data from our group showed that inflammatory gene signatures (SCLC-I) responds better to immunotherapy (IO) than other subtypes. Given association between smoking and inflammation, we hypothesized may correlate IO...
Amivantamab-vmjw (amivantamab) is a bispecific EGFR/MET antibody approved for patients with advanced NSCLC EGFR exon 20 insertion mutations, after prior therapy. Nevertheless, the benefits and safety of amivantamab in other EGFR-mutant lung cancer, or without osimertinib, concurrent radiation therapy, are less known. We queried MD Anderson Lung Cancer GEMINI, Fred Hutchinson Research Center, University California Davis Comprehensive Stanford Center's database treated amivantamab, not on...
IntroductionThe efficacy of targeted therapies in oncogene-driven lung adenocarcinomas (LUADs) has been well established; however, the benefit for EGFR-mutant or ALK-rearranged squamous cell carcinomas (LUSCs) is less known, partially owing to rarity incidence.MethodsWe reviewed database MD Anderson Cancer Center and identified metastatic LUSC with classic EGFR ALK alterations.ResultsThere were eight patients (median age = 58 y) six EML4-ALK 50 who received tyrosine kinase inhibitors (TKIs)...
Background: The benefit of chemotherapy combined with immunotherapy in EGFR-mutant lung adenocarcinoma (LUAD) patients whose tumor developed resistance to EGFR tyrosine kinase inhibitors (TKIs) is not thoroughly investigated. goal this retrospective cohort study assess the clinical efficiency alone or combination a real-world setting. Methods: This enrolled LUAD sensitive mutations had acquired TKIs and received systemic treatment (chemo; n = 84), (chemoIO; 30), plus bevacizumab without IO...
Background Salivary duct carcinoma (SDC) and adenocarcinoma, not otherwise specified (adeno‐NOS), are rare salivary gland cancers. Data on the efficacy of systemic therapy for these diseases limited. Methods were retrospectively collected from patients seen at The University Texas MD Anderson Cancer Center during 1990 to 2020. Objective response rate (ORR) was assessed per RECIST v1.1. Recurrence‐free survival (RFS), progression‐free (PFS), overall (OS) by Kaplan‐Meier method. Cox regression...
NSCLC transformation to SCLC has been best characterized with
Dendritic cells (DCs) transfected with total amplified tumor cell RNA have the potential to induce broad antitumor immune responses. However, analytical methods required for quantitatively assessing integrity, fidelity, and functionality of are lacking. We developed a series assays including gel electrophoresis, northern blot, capping efficiency, microarray analysis determine integrity fidelity model system assess after transfection into human DCs. employed these tools demonstrate that...
Abstract Small-cell lung cancer (SCLC) remains the deadliest histologic subtype with a median survival of only 12.3 months among trial-eligible patients extensive-stage (ES-SCLC) disease, as demonstrated in IMPower133 trial. Heavy tobacco use, >40 pack-years, is strongly associated developing SCLC, which near universally harbors RB1 and TP53 co-mutations. However, there paucity information regarding SCLC tumors that occur minimal use. This represents an unmet need given increasing...
Many targeted therapies to treat genetic mutations in non-small cell lung cancer (NSCLC) have been developed. Amivantamab (Rybrevant), a bispecific antibody targeting the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor, was approved by US Food Drug Administration 2021 for treatment of adult patients with locally advanced or metastatic NSCLC
Introduction: Targeted therapy and immune checkpoint inhibitors (ICI) have drastically improved outcomes of metastatic non-small cell lung cancer (NSCLC) patients in outpatient settings. Because trials on critically ill are improbable, little is known about their efficacy among admitted to intensive care units (ICU). Methods: We retrospectively analyzed the clinical critically-ill NSCLC receiving either ICI or targeted during ICU admission at MD Anderson Cancer Center from April 2016 August...
Meeting abstracts AGS-003 is an autologous dendritic cell immunotherapy consisting of matured DC co-electroporated with amplified tumor RNA and synthetic CD40L RNA. A Phase 2 trial evaluated AGS-003-induced T immunity in RCC patients combination sunitinib. comprehensive
<p>Supplementary figures</p>
<p>Supplementary figures</p>